- 专利标题： RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
-
申请号： US15671220申请日： 2017-08-08
-
公开(公告)号： US10246714B2公开(公告)日： 2019-04-02
- 发明人: Duncan Brown , James J. Cunningham , Marian Gindy , Victoria Pickering , Matthew G. Stanton , Steven M. Stirdivant , Walter R. Strapps
- 申请人： Sirna Therapeutics, Inc.
- 申请人地址： US MA Cambridge
- 专利权人： Sirna Therapeutics, Inc.
- 当前专利权人： Sirna Therapeutics, Inc.
- 当前专利权人地址： US MA Cambridge
- 代理机构： McCarter & English, LLP
- 代理商 Maria Laccotripe Zacharakis; Deborah L. Nagle
- 主分类号： A61K48/00
- IPC分类号： A61K48/00 ; C12N15/11 ; C07H21/02 ; C07H21/04 ; C12N15/113
摘要：
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
公开/授权文献
信息查询
